Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants Joanna Siegall - Senior Manager of Corporate Communications and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Kupfer - SVP and Chief Medical Officer Robert Wong - VP and CAO Ching Jaw - SVP and CFO Andrew Callos - CCO Conference Call Participants Dane Leone - Raymond James Joe Pantginis - H.C. Wainwright Yasmeen Rahimi - Piper Sandler Jeff Hung - Morgan Stanley Akash ...

Sarcomere Directed Therapies | --- | --- | --- | --- | |-------------------|-------|-------|-------| | | | | | | | | | | | EMPOWERING | | | | | MUSCLE EMPOWERING | | | | | LIVES | | | | John, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-lo ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications and Investor Relations Robert Blum - President and Chief Executive Officer Fady Malik - Executive Vice President of R&D Stuart Kupfer - Senior Vice President and Chief Medical Officer Robert Wong - Vice President and Chief Accounting Officer Ching Jaw - Senior Vice President and Chief Financial Officer Andrew Callos - Chief ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Common Stock, $0.001 par value Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duri ...

Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Diane Weiser – Senior Vice President-Corporate Communications and Investor Relations Robert Blum – President and Chief Executive Officer Fady Malik – Executive Vice President-Research and Development Stuart Kupfer – Senior Vice President and Chief Medical Officer Robert Wong – Vice President and Chief Accounting Officer Ching Jaw – Senior Vice President and Chief Financial Officer Andrew Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Common Stock, $0.001 par value Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 dur ...

Sarcomere Directed Therapies | --- | --- | --- | --- | |-------------------|-------|-------|-------| | | | | | | | | | | | EMPOWERING | | | | | MUSCLE EMPOWERING | | | | | LIVES | | | | John, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-lo ...

Cytokinetics, Inc. (NASDAQ:CYTK) Q4 2020 Results Earnings Conference Call February 25, 2021 4:00 PM ET Company Participants Diane Weiser - SVP, Corporate Communications & IR Robert Blum - CEO, President Fady Malik - EVP, Research & Development Stuart Kupfer - SVP & Chief Medical Officer Robert Wong - VP & CAO Ching Jaw - SVP & CFO Conference Call Participants Dane Leone - Raymond James Jason Butler - JMP Securities Joe Pantginis - H.C. Wainwright Salim Syed - Mizuho Charles Duncan - Cantor Fitzgerald Jeff ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 From the transition period from to Commission file number: 000-50633 CYTOKINETICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 94-3291317 (State or other jurisdi ...

Sarcomere Directed Therapies | --- | --- | --- | --- | |------------------|-------|-------|-------| | | | | | | | | | | | EMPOWERING | | | | | MUSCLE | | | | | EMPOWERING LIVES | | | | John, diagnosed with heart failure Jillian, diagnosed with HCM Chuck, diagnosed with ALS Forward-Looking Statements This Presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-loo ...